Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASH2020
ASH2020
TG Therapeutics set for upsized IPO to develop cancer combination drug
Pharmaforum
Tue, 12/15/20 - 10:33 am
TG Therapeutics
ASH2020
IPOs
CLL
TG adds a multiple sclerosis string to its bow
EP Vantage
Fri, 12/11/20 - 11:07 am
TG Therapeutics
hematology
ASH2020
ublituximab
MS
multiple sclerosis
ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
Endpoints
Tue, 12/8/20 - 11:08 pm
ASH2020
Novartis
CML
asciminib
Pfizer
ASH 2020 – Forma gets an early edge over Agios in sickle cell disease
EP Vantage
Tue, 12/8/20 - 10:30 am
ASH2020
Forma Therapeutics
Agios
sickle cell disease
FT-4202
ASH: Takeda pads case for new leukemia use with 5-year survival data
Fierce Pharma
Tue, 12/8/20 - 12:11 am
Takeda
ASH2020
CML
Iclusig
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Fierce Biotech
Mon, 12/7/20 - 10:48 am
ASH2020
Allogene
CAR-T
ASH 2020 – UK biotech's hollow victory
EP Vantage
Mon, 12/7/20 - 10:34 am
ASH2020
Loxo Oncology
LOXO-305
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
Mon, 12/7/20 - 10:32 am
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
#ASH20: Bain execs step in to position a somewhat battered and bruised Syros with a new clinical candidate and enough money to charge ahead
Endpoints
Sun, 12/6/20 - 07:17 pm
Syros
ASH2020
SY-1425
Bain Capital
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
Sun, 12/6/20 - 07:15 pm
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Orca-T Shows Preventative Potential for GVHS in High-Risk Blood Cancers
Targeted Oncology
Sun, 12/6/20 - 07:13 pm
Orca-T
HSCT
ASH2020
graft vs host disease
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment
Fierce Biotech
Sun, 12/6/20 - 07:10 pm
ASH2020
JNJ
bispecifics
Multiple Myeloma
teclistamab
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
Fierce Pharma
Sat, 12/5/20 - 11:38 pm
ASH2020
Novartis
Kymriah
follicular lymphoma
clinical trials
#ASH20: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific
Endpoints
Sat, 12/5/20 - 11:34 pm
ASH2020
Regeneron
Multiple Myeloma
clinical trials
REGN5458
#ASH20: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in mantle cell lymphoma
Endpoints
Sat, 12/5/20 - 11:28 pm
ASH2020
Eli Lilly
clinical trials
LOXO-305
Loxo Oncology
mantle cell lymphoma
non-Hodgkin lymphoma
Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting
Yahoo/Bloomberg
Fri, 12/4/20 - 11:09 am
ASH2020
Trillium Therapeutics
CRISPR Therapeutics
Fate Therapeutics
Vertex Pharmaceuticals